|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01094353 |
|
Date of registration:
|
24/03/2010 |
|
Primary sponsor: |
|
|
Public title:
|
A Comparative Study Minisling Versus Transobturator (TOT)Sling
sui |
|
Scientific title:
|
Randomised Trial of Ophira™ Minisling System and Unitape™ for the Treatment of Stress Urinary Incontinence in Women |
|
Date of first enrolment:
|
June 2008 |
|
Target sample size:
|
50 |
|
Recruitment status: |
Enrolling by invitation |
|
URL:
|
http://clinicaltrials.gov/show/NCT01094353 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Brazil
| | | | | | | |
|
Contacts
|
|
Name:
|
Lucyana m djehdian, Pg |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Federal University of São Paulo |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- clinical and urodynamic diagnosis of SUI in patients between 18 and 90 years
Exclusion Criteria:
- postvoid residual urine volume more than 100 ml, coagulation disorders, current urinary tract infection, sequelae of previous radiation therapy of the pelvis, anticoagulant therapy, vulvovaginitis, and anesthesia contraindication
Age minimum:
18 Years
Age maximum:
90 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Female Stress Urinary Incontinence
|
|
Intervention(s)
|
|
Procedure: minisling ophira™
|
|
Primary Outcome(s)
|
|
to assess efficacy between tot with minisling in cure in women with stress urinary incontinence
[Time Frame: one year]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|